


## FHD-609

Cat. No.:	HY-153367		
CAS No.:	2676211-64-4		
Molecular Formula:	C <sub>47</sub> H <sub>56</sub> N <sub>8</sub> O <sub>6</sub>		
Molecular Weight:	829		
Target:	Epigenetic Reader Domain		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (120.63 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.2063 mL	6.0314 mL	12.0627 mL
		5 mM	0.2413 mL	1.2063 mL	2.4125 mL
10 mM		0.1206 mL	0.6031 mL	1.2063 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	FHD-609 is an inhibitor and a degrader of BRD9 (bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	BRD9

### REFERENCES

---

[1]. Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets. *Expert Opin Ther Targets*. 2022 Mar;26(3):187-192.

[2]. Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. *Cancers (Basel)*. 2022 May 31;14(11):2721.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA